Choudhry Niteesh K, Levin Raisa, Winkelmayer Wolfgang C
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA.
Heart. 2007 Aug;93(8):945-51. doi: 10.1136/hrt.2006.110197. Epub 2007 Mar 7.
To compare the effectiveness of statins of different treatment intensity used to treat elderly patients with acute coronary syndrome (ACS) in typical care settings.
Retrospective cohort study using linked hospital and pharmacy claims data.
Statewide pharmacy benefits programmes in Pennsylvania and New Jersey.
18,311 Medicare patients discharged alive after ACS who received a prescription for a statin within 90 days of hospital discharge.
Using multivariable and propensity-matched Cox proportional hazards regression models, patients who were prescribed high-intensity and moderate-intensity statins were compared based on the drug-dose combination that they initially received. Individual drug-dose combinations were also compared. Our primary outcome was the composite of all-cause death or recurrent ACS.
Patients who received moderate-intensity statins were as likely to experience a primary outcome as patients treated with high-intensity statins (adjusted HR 1.02, 95% CI 0.96 to 1.08). Propensity matching did not change the results. Individually, all moderate-intensity statins were as effective as high-intensity atorvastatin with the exception of lovastatin (adjusted HR 1.22, 95% CI 1.09 to 1.36). Similarly, all high-intensity statins seem as effective as high-intensity atorvastatin but the CIs surrounding these estimates were wide.
This analysis of elderly patients with ACS treated in typical care settings does not demonstrate the superiority of high-intensity over moderate-intensity statin treatment or significant differences among individual statins.
比较在常规护理环境中,不同治疗强度的他汀类药物用于治疗老年急性冠脉综合征(ACS)患者的有效性。
利用医院与药房关联报销数据进行的回顾性队列研究。
宾夕法尼亚州和新泽西州的全州药房福利计划。
18311名ACS后存活出院且在出院90天内接受他汀类药物处方的医疗保险患者。
使用多变量和倾向匹配的Cox比例风险回归模型,根据患者最初接受的药物剂量组合,对接受高强度和中等强度他汀类药物治疗的患者进行比较。还对个体药物剂量组合进行了比较。我们的主要结局是全因死亡或复发性ACS的复合结局。
接受中等强度他汀类药物治疗的患者与接受高强度他汀类药物治疗的患者发生主要结局的可能性相同(校正风险比1.02,95%置信区间0.96至1.08)。倾向匹配并未改变结果。单独来看,除洛伐他汀外,所有中等强度他汀类药物与高强度阿托伐他汀的疗效相同(校正风险比1.22,95%置信区间1.09至1.36)。同样,所有高强度他汀类药物似乎与高强度阿托伐他汀一样有效,但这些估计值周围的置信区间较宽。
对在常规护理环境中接受治疗的老年ACS患者的这项分析未显示高强度他汀类药物治疗优于中等强度他汀类药物治疗,也未显示个体他汀类药物之间存在显著差异。